Table III.
Elbow flexion range of movement (ROM) and strength of the injured elbow together with the Short-Form 36 and Disabilities of the Arm Shoulder and Hand (DASH; Dutch language version) questionnaires and visual analogue scale (VAS) for pain before mononuclear cell (MNC) injection and after three and six months
| Group | ||||||
|---|---|---|---|---|---|---|
| Mean (sd) outcome* | A (n = 3) | B (n = 3) | C (n = 3) | p-value† | Total (n = 9) | |
| Flexion ROM (°) | 0.22 | |||||
| 0 months | 65 (38) | 12 (20) | 30 (52) | 36 (41) | ||
| 3 months | 82 (28) | 115 (5) | 107 (15) | 101 (22) | ||
| 6 months | 88 (20) | 100 (20) | 110 (22) | 99 (20) | ||
| p-value‡ | < 0.001‡ | |||||
| Median flexion strength (MRC grade) (range) | 0.02 | |||||
| 0 months | 3 (3 to 3) | 2 (2 to 3) | 2 (2 to 3) | 2 (2 to 3) | ||
| 3 months | 3 (3 to 3) | 4 (3 to 4) | 4 (3 to 4) | 3 (3 to 4) | ||
| 6 months | 3 (3 to 4) | 4 (4 to 4) | 4 (4 to 4) | 4 (3 to 4) | ||
| p-value‡ | < 0.001‡ | |||||
| SF-36 | 0.06 | |||||
| 0 months | 86 (6) | 57 (16) | 69 (6) | 78 (15) | ||
| 3 months | 91 (5) | 71 (18) | 74 (9) | 78 (14) | ||
| 6 months | 82 (11) | 72 (15) | 75 (10) | 76 (12) | ||
| p-value‡ | 0.06‡ | |||||
| DASH-DLV | 0.15 | |||||
| 0 months | 43 (19) | 35 (25) | 75 (16) | 51 (25) | ||
| 3 months | 64 (39) | 68 (19) | 76 (12) | 69 (23) | ||
| 6 months | 41 (16) | 71 (17) | 74 (16) | 65 (20) | ||
| p-value‡ | 0.09‡ | |||||
| VAS for pain | 0.02 | |||||
| 0 months | 0.8 (0.8) | 6.1 (2.1) | 1.0 (1.1) | 2.7 (2.9) | ||
| 3 months | 0.8 (0.6) | 2.3 (2.0) | 1.3 (1.6) | 1.5 (1.5) | ||
| 6 months | 0.8 (0.6) | 2.0 (0.5) | 2.2 (3.0) | 1.7 (1.7) | ||
| p-value‡ | 0.24‡ | |||||
* MRC, Medical Research Council; SF-36, Short-Form 36 (scored from 0 to 100); DASH-DLV, Disabilities of the Arm Shoulder and Hand – Dutch language version (scored from 0 to 100); VAS, visual analogue scale (scored from 0 (no pain) to 10 (extreme pain) † comparison of differences between pre-op and six months in the groups (mixed model analysis) ‡ difference between pre-op and six month values for all patients (mixed model analysis)